Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Citius Oncology, Inc.NASDAQ: CTOR
Net Receivables · Q2 FY2026 · quarter ended Mar 2026
Net receivables remains negative
Q2 FY2026 net receivables was $1.08M, compared with $0 a year earlier.
Context
- Net receivables amounted to 1.1% of total assets at the end of Q2 FY2026, up 1.1 pp from a year earlier.
- Net receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 0 | — |
| FY2024 | 2024-09-30 | 0 | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Net Receivables vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 net receivables of $1.08M is the 4th highest of the 10 companies compared; the peer median is $655K.
- Net receivables amounts to 1.1% of total assets for CTOR, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $29.85M | +181.1% | -10.5% | 10.2% | |
| Mar 2026 | $19.86M | +20.2% | +12.8% | 22.9% | |
| Mar 2026 | $5.18M | -28.4% | +0.7% | 7.8% | |
CTORCitius Oncology, Inc. | Mar 2026 | $1.08M | — | — | 1.1% |
| Mar 2026 | $704K | -70.7% | -71.2% | 0.2% | |
| Mar 2026 | $655K | — | — | 1.0% | |
| Mar 2026 | $233K | -94.7% | — | 0.2% | |
| Mar 2026 | $44K | -99.8% | +186.1% | 0.1% | |
| Mar 2026 | $0 | — | — | 0.0% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding CTOR) | $655K | -49.6% | +0.7% | 0.2% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.